1,721,267 research outputs found
A placebo-controlled study of the efficacy and tolerability of a nonsteroidal anti-inflammatory drug, DHEP plaster, in inflammatory peri- and extra-articular rheumatological diseases
No full textA double-blind, randomized, placebo-controlled study has been carried out in order to assess the effects of the new topical cutaneous formulation, diclofenac hydroxyethylpyrrolidine (DHEP) plaster. Sixty patients (10 M + 50 F, mean age 56.6 yrs) suffering from local inflammatory processes in peri-articular/tendinous and/or extra-articular sites were involved in this study and randomly given either DHEP plaster or placebo plaster. Plasters were applied and left on the site of inflammation b.i.d. (at 8 a.m. and 8 p.m.) for 14 days. Patients under stabilized systemic treatment with NSAIDs, glucocorticoids and/or basic therapy for over 2 months, maintained this treatment unchanged during the course of the study. Patients were examined on days 3, 5, 7 and 14. The effects of the treatments were assessed using subjective, semi-quantitative (provoked pain, peri-articular swelling, doctor-patient judgement, telethermographic index) and quantitative variables (spontaneous pain measured using a visual analogical scale). In the peri-articular pathologies, spontaneous and provoked pain decreased faster and in a clinically relevant manner in the group treated with DHEP plaster compared to the control group (p < 0.01). Local inflammation, objectively evaluated using the telethermographic index, showed consistent reduction during the study which was statistically significant from day 3 onwards and significantly different compared to the control group. Global assessment of efficacy, expressed by the investigator and the patients, was significantly better (good to excellent after only 7 days in 70% of the cases) in the DHEP group compared to the placebo group. In the extra-articular pathologies, results similar to those reported earlier were obtained.(ABSTRACT TRUNCATED AT 250 WORDS
Comparative examination of the treatment of patients with arthrosis using Ibuprofen and Fenoprofen
No full textClinical pharmacology of a slow-release ketoprofen preparation: a double-blind, crossover comparison with plain ketoprofen in rheumatoid arthritis
No full textForty out-patients with rheumatoid arthritis took part in a double-blind crossover trial to compare the short-term effectiveness and safety of two formulations of oral ketoprofen, i.e., plain and slow-release capsules, each given for one week without any interval between treatments. The daily dosage, 300 mg in both cases, was split in, respectively, three and two doses. Significant improvements were found in all variables studied (pain at rest, pain on active motion, quality of sleep, duration of morning stiffness, grip strength, Ritchie's articular index) with both regimens, but no significant differences were detected between them. The patients' estimates of the overall response to the two treatments coincided. Adverse reactions were limited to mild pyrosis in one patient who was receiving plain ketoprofen. The results of the present trial are consistent with previous findings in osteoarthritic patients, indicating that the two formulations are virtually equivalent in use
Proglumetacin in osteoarthritis: Efficacy in short-term treatment [Efficacia a breve termine della proglumetacina nell'artrosi]
No full textProglumetacin was administered as a sole treatment during 15 days at 450 mg/day to 20 patients with osteoarthritis localized in several joints. Within the observation period, pain at rest and on loading, joint mobility and morning stiffness improved significantly. Tolerance also resulted very good, as only two patients reported mild and transient gastric upsets. The peculiar combination of good efficacy also in short-term treatment and very good tolerance, points to proglumetacin as a drug of choice for the ambulatory management also of degenerative-reactive joint disorders
Evaluation of the efficacy and tolerability of a new non-steroid anti-inflammatory agent, isoxicam [Valutazione dell'efficacia e della tollerabilità di un nuovo antiflogistico non steroideo, l'isoxicam]
No full textSixty patients with osteoarthritis of the column, hip or knee, rheumatoid arthritis, musculoskeletal disorders, entered an open study to evaluate the efficacy and tolerance of a new anti-inflammatory drug, isoxicam, 200 mg once daily per os or 300 mg suppositories once a day. Both treatments reduced the severity of the clinical symptoms of the diseases and the drug was well tolerated. No patient showed adverse effects
Flurbiprofen in rheumatoid arthritis: A long-term experience
No full textThe present experience confirms the effectiveness of flurbiprofen in the treatment of rheumatoid arthritis. Significant improvements occurred within the first two months of treatment with a stabilization during the following period. No parameter worsened at the long-term observation and a very low rate of subjects (2/20, 10%) complained of slight and transitory gastrointestinal troubles. Referring to the twofold question proposed undertaking this trial, the results exclude a loss of efficacy of flurbiprofen after the first months of treatment and support of the good safety of this drug also in the long-term period
A short-term, double-blind comparison between indoprofen and diclofenac in osteoarthritis
No full text
- …
